Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/nyas.13114 http://scihub22266oqcxt.onion/10.1111/nyas.13114 C4940216!4940216!27308865     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Ann+N+Y+Acad+Sci 2016 ; 1374 (1): 202-9 Nephropedia Template TP {{tp|p=27308865|t=2016. Development of sulfanegen for mass cyanide casualties |pdf=|usr=}}{{27308865}} gab.com Text Development of sulfanegen for mass cyanide casualties JO: Ann N Y Acad Sci http://www.kidney.de/pget.php?&tw=1&pmid=27308865 #FOAvip Cyanide is a metabolic poison that inhibits the utilization of oxygen to form ATP. The consequences of acute cyanide exposure are severe, and result in loss of consciousness, cardiac and respiratory failure, hypoxic brain injury, and dose-dependent death within minutes to hours. In a mass-casualty scenario, such as an industrial accident or terrorist attack, currently available cyanide antidotes would leave many victims untreated in the short time available for successful administration of a medical countermeasure. This restricted therapeutic window reflects the rate-limiting step of intravenous administration, which requires both time and trained medical personnel. Therefore, there is a need for rapidly acting antidotes that can be quickly administered to large numbers of people. To meet this need, our lab is developing sulfanegen, a potential antidote for cyanide poisoning with a novel mechanism based on 3-mercaptopyruvate sulfurtransferase (3-MST) for the detoxification of cyanide. Additionally, sulfanegen can be rapidly administered by intramuscular injection and has shown efficacy in many species of animal models. The following summarizes the journey from concept to clinical leads for this promising antidote. Twit Text FOAVip Development of sulfanegen for mass cyanide casualties ????Ann N Y Acad Sci http://www.kidney.de/pget.php?&tw=1&pmid=27308865 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27308865 #FOAvip English Wikipedia <ref>{{Cite pmid|27308865}}</ref> Development of sulfanegen for mass cyanide casualties #MMPMID27308865 Patterson SE; Moeller B; Nagasawa HT; Vince R; Crankshaw DL; Briggs J; Stutelberg MW; Vinnakota CV; Logue BA Ann N Y Acad Sci 2016[Jun]; 1374 (1): 202-9 PMID27308865show ga Cyanide is a metabolic poison that inhibits the utilization of oxygen to form ATP. The consequences of acute cyanide exposure are severe, and result in loss of consciousness, cardiac and respiratory failure, hypoxic brain injury, and dose-dependent death within minutes to hours. In a mass-casualty scenario, such as an industrial accident or terrorist attack, currently available cyanide antidotes would leave many victims untreated in the short time available for successful administration of a medical countermeasure. This restricted therapeutic window reflects the rate-limiting step of intravenous administration, which requires both time and trained medical personnel. Therefore, there is a need for rapidly acting antidotes that can be quickly administered to large numbers of people. To meet this need, our lab is developing sulfanegen, a potential antidote for cyanide poisoning with a novel mechanism based on 3-mercaptopyruvate sulfurtransferase (3-MST) for the detoxification of cyanide. Additionally, sulfanegen can be rapidly administered by intramuscular injection and has shown efficacy in many species of animal models. The following summarizes the journey from concept to clinical leads for this promising antidote. äDevelopment of sulfanegen for mass cyanide casualties (epmc).pdf DeepDyve Pubget Overpricing